Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 35 of 37, showing 5 Applications out of 183 total, starting on record 171, ending on 175

# Protocol No Study Title Investigator(s) & Site(s)

171.

ECCT/22/11/03   BFAST
    A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL)   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
View

172.

ECCT/21/06/13   CARES
    A Phase 3b, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy, Safety,   and Tolerability of Switching to Long-Acting Cabotegravir Plus Long-Acting Rilpivirine   From Current Antiretroviral Regimen in HIV-1 Infected, Virologically Suppressed Adults   in Sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
3. Aga khan University Hospital (Nairobi City county)
 
View

173.

ECCT/23/03/04   CONSTELLATION
    A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants   
Principal Investigator(s)
1. Dr Lucas Otieno Tina
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
 
View

174.

ECCT/24/03/04   MK8591A-053 Trial
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
2. Nelly Rwamba Mugo
Site(s) in Kenya
1. Site 8650, KEMRI-CMR-RCTP, Kisumu (Kisumu county)
2. Site 8651, KEMRI-CCR-PHRD, Thika (Kiambu county)
3. Site 8652, KEMRI-CCR, NAIROBI (Nairobi City county)
 
View

175.

ECCT/22/03/02   MOVe AHEAD STUDY
    A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection With Symptoms) in Adults Residing With a Person With COVID-19   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI RCTP KISUMU
 
View